Ontology highlight
ABSTRACT: Background
Sickle cell disease (SCD) and its complications contribute to high rates of morbidity and early mortality and high cost in the United States and African heritage community.Objective
To evaluate the cost-effectiveness of gene therapy for SCD and its value-based prices (VBPs).Design
Comparative modeling analysis across 2 independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) using the same databases.Data sources
Centers for Medicare & Medicaid Services claims data, 2008 to 2016; published literature.Target population
Persons eligible for gene therapy.Time horizon</
SUBMITTER: Basu A
PROVIDER: S-EPMC11657757 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature